Introduction. Effective and timely treatment of diabetes can substantially reduce the negative impact. Today many therapeutic options are available with new classes of drugs (DPP-4 inhibitors, GLP-1 analogs, SGLT-2 inhibitors) added to others used for a long time. These drugs differ in mechanism of action, tolerability and costs, while presenting similar efficacy. The choice of the best therapy for the individual patient, however, is complicated by the scarcity of studies which directly compare single drugs or their combinations
Aims. Using advanced statistical techniques (network metanalysis) to combine literature data, the study addresses the physicians’ questions and guidelines recommendations: which is the best monotherapy? When monotherapy is not enough, which is the best two-drugs combination? Again, which combination of three drugs is preferred when two are not enough?
Type of study. International network metanalysis
Population. Data from 301 randomized clinical trials involving 118,094 patients with type 2 diabetes
Centers. The study was conducted by reseaerchers from Italy, Australia, New Zealand, Canada and Greece
Promoters. CORESEARCH, University of Bari, University of Otago Christchurch-New Zealand
Funding. Royal Society of New Zealand
Status. Ongoing study
- Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, Maggo J, Gray V, De Berardis G, Ruospo M, Natale P, Saglimbene V, Badve SV, Cho Y, Nadeau-Fredette AC, Burke M, Faruque L, Lloyd A, Ahmad N, Liu Y, Tiv S, Wiebe N, Strippoli GF. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA. 2016;316:313-24.